pmc logo imageJournal ListSearchpmc logo image
Logo of aacAntimicrob Agents Chemother SubscriptionsAntimicrob Agents Chemother Web Site
Antimicrob Agents Chemother. 1990 December; 34(12): 2398–2401.
PMCID: PMC172068
Intraprostatic distribution of lomefloxacin following multiple-dose administration.
J M Kovarik, J A de Hond, I M Hoepelman, T Boon, and J Verhoef
Department of Clinical Microbiology, University Hospital Utrecht, The Netherlands.
Abstract
The ability of lomefloxacin to penetrate and distribute within the human prostate was assessed in 20 patients undergoing elective prostate surgery (18 transurethral prostatic resections and 2 prostatectomies). Subjects were middle-aged to elderly (mean age +/- standard deviation, 69.8 +/- 8.2 years) with normal hepatic function and with creatinine clearances ranging from 35.8 to 141 ml/min/1.73 m2. Lomefloxacin was administered in 400-mg doses orally every 24 h. Its disposition was characterized following the third dose by obtaining multiple serum samples and intraoperative paired central zone and peripheral zone prostate tissue samples. Lomefloxacin concentrations were determined by a validated high-performance liquid chromatography method with fluorescence detection. Concentrations in serum during the perioperative period declined from 3.1 +/- 1.0 mg/liter (mean +/- standard deviation) at 1 h postdose to 2.3 +/- 0.7 mg/liter at 6 h postdose. The time of tissue extraction ranged from 0.1 to 7.1 h postdose. Intraoperative serum lomefloxacin concentrations ranged from 0.5 to 4.8 (median, 2.4) mg/liter, while prostate tissue concentrations ranged from 1.1 to 10.1 (median, 5.4) mg/kg of tissue for the central zone and 0.9 to 6.5 (median, 5.2) mg/kg for the peripheral zone. Intraindividual paired prostate concentrations (central zone versus peripheral zone) were not statistically different. The partition coefficient (ratio of concentration in prostate to concentration in serum) for the central zone was 2.2 +/- 0.6 (range, 1.2 to 3.1), and for the peripheral zone it was 2.1 +/- 0.7 (range, 1.2 to 4.2). Lomefloxacin exhibited good penetration into the human prostate with homogeneous intraprostatic distribution following multiple-dose administration.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (803K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Barza, M; Cuchural, G. The penetration of antibiotics into the prostate in chronic bacterial prostatitis. Eur J Clin Microbiol. 1984 Dec;3(6):503–505. [PubMed]
  • Chin, NX; Novelli, A; Neu, HC. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrob Agents Chemother. 1988 May;32(5):656–662. [PubMed]
  • Fair, WR; Cordonnier, JJ. The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol. 1978 Dec;120(6):695–698. [PubMed]
  • Gorelick, JI; Senterfit, LB; Vaughan, ED., Jr Quantitative bacterial tissue cultures from 209 prostatectomy specimens: findings and implications. J Urol. 1988 Jan;139(1):57–60. [PubMed]
  • Grabe, M. Antimicrobial agents in transurethral prostatic resection. J Urol. 1987 Aug;138(2):245–252. [PubMed]
  • Hirose, T; Okezaki, E; Kato, H; Ito, Y; Inoue, M; Mitsuhashi, S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854–859. [PubMed]
  • Kenny, GE; Hooton, TM; Roberts, MC; Cartwright, FD; Hoyt, J. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother. 1989 Jan;33(1):103–107. [PubMed]
  • Leroy, A; Fillastre, JP; Humbert, G. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 1990 Jan;34(1):17–20. [PubMed]
  • McNeal, JE. The prostate and prostatic urethra: a morphologic synthesis. J Urol. 1972 Jun;107(6):1008–1016. [PubMed]
  • Morrison, PJ; Mant, TG; Norman, GT; Robinson, J; Kunka, RL. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrob Agents Chemother. 1988 Oct;32(10):1503–1507. [PubMed]
  • Orland, SM; Hanno, PM; Wein, AJ. Prostatitis, prostatosis, and prostatodynia. Urology. 1985 May;25(5):439–459. [PubMed]
  • Schentag, JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet. 1989;16 Suppl 1:25–31. [PubMed]
  • Sörgel, F; Jaehde, U; Naber, K; Stephan, U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989;16 Suppl 1:5–24. [PubMed]
  • Stone, JW; Andrews, JM; Ashby, JP; Griggs, D; Wise, R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. [PubMed]
  • Wise, R; Andrews, JM; Ashby, JP; Matthews, RS. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1988 May;32(5):617–622. [PubMed]